

# SOMETHING BETTER THAN HOPE

CIRM Business Development Update

ICOC Meeting

June 18, 2021

**Shyam Patel, Ph.D.**  
Director, Business Development








## CIRM-Funded Projects Attract Industry Support

CIRM's funding model accelerates and de-risks therapeutic development programs until they obtain early data to attract industry partnerships.

### Highlighted Measures of Industry Partnering by CIRM-funded projects:

- Over 50% of CIRM-funded Clinical Projects are partnered with Industry.
- 6 CIRM-funded companies have gone public & 4 were acquired.
- CIRM-funded projects have attracted at least \$18.2B in industry investments.
- CIRM funding of academic projects has contributed to the spin out of 46 companies.
- Industry partnering of CIRM-funded projects has potential to generate returns for the state.

## 2021: Highlighted Industry Partnering Events

	Allogeneic Cell Immunotherapies for COVID & Cancer	<b>SPAC Acquisition - \$372M in proceeds</b>
	Non-toxic conditioning and cell engineering for HSC transplants	<b>SPAC Acquisition - \$200M in proceeds</b>
	CRISPR Therapies for Blood Disorders	<b>\$150M Series B Venture Financing</b>
	Cells Therapy for Spinal Cord Injury	<b>\$57M At-the-Market Offering &amp; Sale of Holdings</b>
	Allogeneic Cell Immunotherapies for Cancer	<b>\$52M Series A Financing</b>



INDUSTRY  
**ALLIANCE**  
PROGRAM

***CIRM's Industry Alliance Program (IAP):** A unique opportunity for the industry to partner with CIRM in accelerating clinical and preclinical stem cell, gene and regenerative medicine therapy programs to market.*

**VIVO**  
CAPITAL



PANACEA VENTURE  
HEALTHCARE



**BlueRock**  
Therapeutics




**FREQUENCY**  
THERAPEUTICS



**elevatebio**



8VC



SYNTHEGO

**CIRM**  
CALIFORNIA'S STEM CELL AGENCY

# CIRM Partner Day Hosted by Biocom (March 2021)

## Public Plenary Session – March 9

- CIRM Presentation on Funding Model
- 2 Panels Sessions
  - Partnered CIRM Grantees: Jasper Therapeutics, Poseida Therapeutics, Viacyte, Rocket Pharma
  - Emerging Advanced Therapies: Dr. Diana Farmer (UCD), Dr. Anthony Oro (Stanford), Dr. Jack Reidling (Dr. Thompson Lab, UCI)
- 129 Attendees representing Academia, Biotech, Biopharma, Investors
- Event recorded and hosted on CIRM Youtube channel



## 1:1 Meetings between CIRM Grantees & Biocom Industry Partners

- 30 CIRM Grantees
- 21 Biocom Industry Partners

## 1:1 Meetings between Potential Applicants & CIRM

- 17 Requests



## CIRM Manufacturing in California Workshop – April 14, 2021

CIRM convened an all-day virtual workshop of over 50 leaders in cell and gene therapy manufacturing to help it define collaborative solutions to the manufacturing and workforce needs in California.

- Leaders represented:
  - Academic GMP Manufacturing Facilities
  - Community Colleges
  - CDMOs
  - Supply Chain Partners
  - CIRM Grantees & IAP Partners
  - NCATS
  - Consulting Groups



# CIRM Manufacturing in California Workshop – Three Themes

**Session 1** - Incorporating Practical QbD Principles in Cell and Gene Therapy Manufacturing Development

**Session 2** - Operationalizing a Public-Private CA Manufacturing Network

**Session 3** - Training a Diverse Manufacturing Workforce

## CIRM Manufacturing in California Workshop – Key Takeaways

- Empower academic innovators to adopt manufacturing best practices
- Enable competency hubs and GMP manufacturing centers of excellence
- Build a public-private manufacturing network that supports projects from early translation to commercialization
- Leverage CIRM education programs and the public-private network to build faster on-ramps for manufacturing career pathways